Vertex Pharmaceuticals Incorporated (VRTX) Given Buy Rating at Credit Suisse

Vertex Pharmaceuticals Incorporated (VRTX) Given Buy Rating at Credit Suisse


A number of other equities analysts also recently weighed in on the company. Goldman Sachs dropped their target price on Vertex Pharmaceuticals from $135.00 to $129.00 in a report on Monday, February 22nd.



from Biotech News